Goal: To investigate the clinical benefits of partial body weight support for the function of Cardiopulmonary and Cardiac autonomic nerve in the early stage of Heart failure rehabilitation. Materials and Methods: We selected 90 patients with heart failure, divided into observation group (n = 45) and control group (n = 45). Both patients had the conventional drug therapy, while the observation group had the partial body weight support additionally within the 3 months treatment period. Serological examination includes brain natriuretic peptide (BNP) and aldosterone. Echocardiography detects left ventricular morphology, cardiac ejection function (EF) and cardiac autonomic nerve function. Minnesota quality of life scale (MHL) evaluates the life quality of the patients. Results: Before any treatment, there is no significant difference of serum brain natriuretic peptide (BNP), aldosterone, cardiac autonomic nerve function and the Minnesota quality of life scale (MHL) (P > 0.05). After treatment, outcome measures declined, including serum brain natriuretic peptide (BNP) and aldosterone (P < 0.01), LVESD and ESV (P < 0.01), LVEDD and EDV (P > 0.05). Outcome measures raised, including SV, CI, EF%, ΔD%. Among them, EF% had significant difference with P value < 0.05, and ΔD% with P value < 0.01. Both LF and HF raised, but LF/HF declined. The Minnesota quality of life scale (MHL) is significantly lower than before. Conclusion: Partial body weight support obviously reduces serum brain natriuretic peptide (BNP) and aldosterone, as well as improves the function of cardiopulmonary and cardiac autonomic nerve of the patients with heart failure, which at last improves the life quality.

No abstract